Medicare高风险标准与颈动脉血运重建术后结局的关联
本研究基于VQI数据库2013-2016年51,942例颈动脉血运重建患者,验证CMS高风险标准对CAS与CEA术后卒中的区分效力。粗分析中CAS术后30天和2年卒中率均高于CEA;匹配后高风险组CAS卒中风险仍显著高于CEA,而正常风险组两者相似。提示CAS在正常风险患者中的价值可能被低估,在高风险患者中的获益可能被高估。
要点
- 高风险组匹配后CAS较CEA的30天卒中风险显著升高(HR 1.90)。
- 正常风险组匹配后CAS与CEA的30天和2年卒中风险相似。
- CMS高风险标准对CAS获益的区分效力需重新评估。
核心结论
- CAS在正常风险患者中的效用可能被低估,而在高风险患者中的潜在获益可能被高估。
- 强烈建议重新评估识别CEA高风险患者的标准及CAS适应证的全国指南。
研究设计与样本
- 回顾性队列研究,纳入VQI数据库2013-2016年所有接受CAS(含栓塞保护)或CEA的患者。
- 共51,942例患者(CAS 7,030例;CEA 44,912例),依据CMS标准分为正常风险组和高风险组。
- 采用1:1粗化精确匹配(2,920对,匹配18个术前变量)和多变量Cox比例风险模型比较CAS与CEA的30天和2年卒中结局。
主要发现
- 粗分析中CAS术后30天卒中率在正常风险组为1.7% vs CEA 1.0%,高风险组为2.5% vs 1.4%(P < .001)。
- 粗分析中CAS术后2年卒中率在正常风险组为1.9% vs CEA 1.0%,高风险组为2.4% vs 1.3%(P < .001)。
- 匹配后高风险组CAS的30天卒中风险仍高于CEA(HR 1.90;95% CI 1.26-2.85),2年风险亦高(HR 1.65;95% CI 1.05-2.60)。
- 匹配后正常风险组CAS与CEA的30天卒中风险相似(HR 0.97;95% CI 0.48-1.95),2年风险亦相似(HR 1.49;95% CI 0.76-2.90)。
关键数值与推荐
- CMS高风险标准用于筛选适合CAS的患者,但此前从未被验证。
- 本研究以CMS标准将患者分为正常风险和高风险组,比较CAS与CEA的30天和2年卒中结局。
临床怎么用
- 在正常风险患者中,CAS与CEA的卒中风险相似,CAS的临床应用价值可能被低估。
- 在高风险患者中,CAS较CEA的卒中风险显著升高,CMS高风险标准筛选出的CAS获益可能被高估。
- 需重新审视CMS高风险标准及CAS适应证指南,以优化患者选择。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The U.S. Centers for Medicare and Medicaid Services (CMS) has defined a set of high-risk criteria to help define patients who are appropriate for carotid artery stenting (CAS), but these criteria have never been validated. We aimed to validate the CMS high-risk criteria in a nationally representative cohort of patients undergoing CAS and carotid endarterectomy (CEA). METHODS: All patients undergoing CAS (with embolic protection) or CEA in the Vascular Quality Initiative (VQI) database (2013-2016) were included. Patients were stratified as being at normal risk (Nr) or high risk (Hr) for undergoing CEA on the basis of CMS criteria. Thirty-day and 2-year stroke outcomes were compared for CAS vs CEA in both the Nr and Hr groups using 1:1 coarsened exact matching and multivariable Cox proportional hazards modeling. RESULTS: A total of 51,942 patients (CAS, 7030; CEA, 44,912) underwent carotid revascularization during the study period. Thirty-day (Nr, 1.7% vs 1.0%; Hr, 2.5% vs 1.4%) and 2-year (Nr, 1.9% vs 1.0%; Hr, 2.4% vs 1.3%) stroke occurred more frequently after CAS vs CEA on crude analysis (P < .001). After matching 2920 pairs of patients on 18 preoperative variables, the risk of 30-day and 2-year stroke remained higher after CAS in the Hr group (30-day risk: hazard ratio [HR], 1.90; 95% confidence interval [CI], 1.26-2.85; 2-year risk: HR, 1.65; 95% CI, 1.05-2.60) but was similar for CAS vs CEA in the Nr group (30-day risk: HR, 0.97; 95% CI, 0.48-1.95; 2-year risk: HR, 1.49; 95% CI, 0.76-2.90). CONCLUSIONS: These data suggest that the utility of CAS in Nr patients may be underappreciated, whereas the potential benefit of CAS in Hr patients may be overestimated. Re-evaluation of the criteria for identifying patients at high risk for CEA and the national guidelines on the indications for CAS is strongly indicated.
引用
- Hicks CW, Nejim B, Locham S, et al. Association between Medicare high-risk criteria and outcomes after carotid revascularization procedures. J Vasc Surg. 2018. PMID: 29361324. doi:10.1016/j.jvs.2017.10.066
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。